Adnexus Therapeutics
2002
FOUNDED
M&A
STATUS
101-200
EMPLOYEES
M&A
LATEST DEAL TYPE
$430M
LATEST DEAL AMOUNT
Description
Developer of Adnectins biologics/medicines in the United States. The company's product candidates include Angiocept/CT-322, an anti-angiogenesis agent for treating cancer that blocks the VEGFR-2 pathway; and other Adnectin therapies for the treatment of oncology, immunology, and cardiovascular diseases.
Website
Formerly Known As
Compound Therapeutics
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Acquirer
Primary Office
- 100 Beaver Street
- Waltham, MA 02453
- United States
+1 (781) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Adnexus Therapeutics’s full profile, request a free trial.
Adnexus Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 24-Sep-2007 | $430M | 000.00 | 00000 | Completed | Startup |
| 6. IPO | 21-Aug-2007 | 000.00 | Cancelled | Clinical Trials - Phase 2 | ||
| 5. Early Stage VC | 07-Aug-2007 | 000.00 | 000.00 | Completed | Startup | |
| 4. Early Stage VC (Series B) | 20-Jun-2006 | 0000 | 000.00 | Completed | Startup | |
| 3. Convertible Debt | 24-May-2006 | 00.00 | 000.00 | Completed | Startup | |
| 2. Early Stage VC | 28-Dec-2004 | $15.6M | $22.1M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 03-Apr-2003 | $6.5M | $6.5M | Completed | Startup |
Adnexus Therapeutics Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Applied Genomic Technology Capital Fund | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Atlas Venture | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Flagship Pioneering | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| HBM Healthcare Investments | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Polaris Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
Adnexus Therapeutics Executive Team (9)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Bruce Silver MD | Medical Director | ||
| Cliff Bechtold | Vice President, Strategic Operations |
7 Former Executives
You’re viewing 2 of 9 executives. Get the full list »